Dietary total antioxidant capacity (TAC) among candidates for coronary artery bypass grafting (CABG) surgery: Emphasis to possible beneficial role of TAC on serum vitamin D.

Plain-language guide to PMID 30540842 (2018): clinical trial of Vitamin D, K2, Magnesium and Zinc in 454 patients.

Key Facts

PMID: 30540842
Journal: PloS one
Year: 2018
Study type: Clinical Trial
Authors: Abbasalizad Farhangi M et al. (2 authors)
DOI: 10.1371/journal.pone.0208806

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this clinical trial publication.

Recently, the clinical importance of total antioxidant capacity (TAC) and its protective role against several chronic diseases like cardiovascular disease, osteoporosis and several types of cancers has been reported.

However, its association with cardio-metabolic risk factors among patients candidate for coronary artery bypass graft surgery (CABG) has not been evaluated yet.

Who Took Part

The study group was 454 patients.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In the current cross-sectional study, 454 patients aged 35-80 years as candidates of CABG and hospitalized in Tehran Heart Center were enrolled.

Anthropometric and demographic characteristics were obtained from all participants.

How the Study Was Run

Total dietary antioxidant capacity (TAC) was calculated according to the findings of semi-quantitative food-frequency questionnaire (FFQ).

Biochemical parameters including serum lipids, albumin, creatinine, HbA1C, C-reactive protein (CRP), lipoprotein (a), creatinine, blood urea nitrogen (BUN) and serum vitamin D concentrations were also assessed by commercial laboratory methods.

What Was Measured

The subject headings attached to it are Antioxidants, C-Reactive Protein, Coronary Artery Bypass, Food Preferences, Glycated Hemoglobin, Hypertension and Iran.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 454 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.